1. Home
  2. INSG vs IBIO Comparison

INSG vs IBIO Comparison

Compare INSG & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Inseego Corp.

INSG

Inseego Corp.

HOLD

Current Price

$4.33

Market Cap

59.2M

ML Signal

HOLD

Logo iBio Inc.

IBIO

iBio Inc.

BUY

Current Price

$0.89

Market Cap

56.0M

Sector

Health Care

ML Signal

BUY

Company Overview

Basic Information
Metric
INSG
IBIO
Founded
1996
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
59.2M
56.0M
IPO Year
2000
2009

Fundamental Metrics

Financial Performance
Metric
INSG
IBIO
Price
$4.33
$0.89
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
9
Target Price
★ $13.67
$5.69
AVG Volume (30 Days)
331.9K
★ 780.5K
Earning Date
11-05-2026
11-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 81.71
EPS
★ 0.13
N/A
Revenue
★ $313,832,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$10.21
N/A
P/E Ratio
$35.19
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$3.58
$0.79
52 Week High
$21.90
$3.82

Technical Indicators

Market Signals
Indicator
INSG
IBIO
Relative Strength Index (RSI) 47.44 23.91
Support Level $3.96 N/A
Resistance Level $4.61 $1.52
Average True Range (ATR) 0.27 0.08
MACD 0.10 -0.03
Stochastic Oscillator 57.10 9.49

Price Performance

Historical Comparison
INSG
IBIO

About INSG Inseego Corp.

Inseego Corp is involved in the design and development of fixed and mobile wireless solutions (4G and 5G NR), Industrial Internet of Things, and cloud solutions for enterprises, service providers, small and medium-sized businesses, governments, and consumers around the globe. Its products and services include intelligent mobile hotspots, wireless routers for IoT applications, USB modems, integrated telematics and mobile tracking devices, which are supported by application software and cloud services designed to enable customers to analyze data insights and configure and manage their hardware easily. It generates maximum revenue from the United States and Canada. The company also has a presence in Europe (including the United Kingdom).

About IBIO iBio Inc.

iBio Inc is a clinical-stage biotechnology company using Artificial Intelligence (AI) for the development of hard-to-drug precision antibodies for obesity, cardiometabolic, and cardiopulmonary diseases. Its product candidate pipeline includes IBIO-610, a monoclonal antibody designed to block Activin E; IBIO-800, a bispecific antibody program targeting myostatin, growth differentiation factor 11 (GDF11), and Activin A; IBIO-600; Amylin Antibody; and Target 4, in different stages of development, being developed as potential therapies for obesity and cardiometabolic disease. The company operates as one reportable segment, which is that of a biotechnology company leveraging AI and ML for the development of hard-to-drug precision antibodies.

Share on Social Networks: